Meeting
2024 ASCO Annual Meeting
Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II trial (CABATEN / GETNE-T1914).
Authors
Jorge Hernando
Medical Oncology Department. Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain
Jorge Hernando , Javier Molina-Cerrillo , Enrique Grande , Marta Benavent Viñuales , Rocio Garcia-Carbonero , Alex Teule , Ana Custodio , Paula Jimenez-Fonseca , Cinta Hierro , Carlos López López , Isabel Sevilla , Marta Llanos , Alberto Carmona-Bayonas , Vicente Alonso , Javier Gallego , Inmaculada Gallego Jiménez , Alberto Orta , Fernando Franco , Alejandro García-Álvarez , Jaume Capdevila
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
2019-002279-32
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4128)
DOI
10.1200/JCO.2024.42.16_suppl.4128
Abstract #
4128
Poster Bd #
108
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (LASER).
First Author: Nicholas I. Simon
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of body mass index (BMI) on efficacy of immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: David Lynn
Poster
2023 ASCO Annual Meeting
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
First Author: Thierry Landre
Poster
2023 ASCO Annual Meeting
Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study.
First Author: Federica Marmorino